Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). A multicenter, non-randomized, open, prospective clinical trial - CML-paed-II-Study

THE TECHNICAL UNIVERSITY OF DRESDE0 个研究点目标入组 150 人开始时间: 2008年2月6日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•- Newly diagnosed Ph+ or BCR-ABL-positive CML - Male and female patients aged 0 to 18 years - Written informed consent
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- CML without BCR-ABL rearrangement detectable by PCR - Pretreatment with Interferon-alpha or any other cytostatic drug with the exception of hydroxyurea or anagrelide (Note: anagrelide is not approved in Germany for treatment of CML). However, these patients may be registered as observational patients. - Any other severe underlying disease beside CML. - Age > 18 years - Pregnant or lactating women - Subjects unlikely to comply with the requirements of the protocol

发起方

THE TECHNICAL UNIVERSITY OF DRESDE